Third case of PML reported to Novartis

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Third case of PML reported to Novartis

Post by MSUK » Wed Aug 19, 2015 4:06 am

Novartis has been notified of a third case of progressive multifocal leukoencephalopathy (PML) in a patient with relapsing multiple sclerosis (MS) treated with Gilenya... Read More - http://www.ms-uk.org/gilenya
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post